Your browser doesn't support javascript.
loading
Antitumor Effect of Platinum-Modified STING Agonist MSA-2.
Wang, Mo; Cai, Ya; He, Tian; Zhang, Yuhang; Yi, Lirong; Li, Wenqing; Zhou, Peng.
Afiliação
  • Wang M; Institute of Reproductive Medicine, School of Medicine, Nantong University, Nantong 226000, China.
  • Cai Y; Institute of Reproductive Medicine, School of Medicine, Nantong University, Nantong 226000, China.
  • He T; Institute of Reproductive Medicine, School of Medicine, Nantong University, Nantong 226000, China.
  • Zhang Y; Institute of Reproductive Medicine, School of Medicine, Nantong University, Nantong 226000, China.
  • Yi L; Institute of Reproductive Medicine, School of Medicine, Nantong University, Nantong 226000, China.
  • Li W; Institute of Reproductive Medicine, School of Medicine, Nantong University, Nantong 226000, China.
  • Zhou P; Institute of Reproductive Medicine, School of Medicine, Nantong University, Nantong 226000, China.
ACS Omega ; 9(2): 2650-2656, 2024 Jan 16.
Article em En | MEDLINE | ID: mdl-38250379
ABSTRACT
The stimulator of interferon genes (STING)-activated innate immune pathway is strong and durable for tumor immunotherapy. MSA-2 is an available non-nucleotide human STING agonist that promotes the tumor immunotherapy of STING activation. However, strategies for remolding and improving the immunotherapy effects of MSA-2 are of value for clinical applications. Here, we synthesized the platinum salt-modified MSA-2 (MSA-2-Pt) due to platinum salt being a classic chemotherapeutic drug. We found that MSA-2-Pt could achieve double-effect antitumor immunotherapy, including inducing cell death by platinum and activating the STING pathway by MSA-2. In the colon carcinoma MC38 model (sensitive to immune checkpoint immunotherapy tumor) and melanoma B16F10 model (poorly immunogenic and highly aggressive tumor), the MSA-2-Pt had a good antitumor effect, which was a little better than MSA-2 with intratumor injections. The results present a promising strategy for STING activation in tumor immunotherapy and broadening platinum-based drugs.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: ACS Omega Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: ACS Omega Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos